(Q36673573)

English

Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial

scientific article published on December 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 August 2017

Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial (English)

1 reference

Europe PubMed Central

15 August 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Simone Mathoulin-Pélissier

8

object named as

S Mathoulin-Pélissier

1 reference

Europe PubMed Central

15 August 2017

author name string

A Ravaud

1

1 reference

Europe PubMed Central

15 August 2017

N Trufflandier

2

1 reference

Europe PubMed Central

15 August 2017

J M Ferrière

3

1 reference

Europe PubMed Central

15 August 2017

M Debled

4

1 reference

Europe PubMed Central

15 August 2017

J Palussière

5

1 reference

Europe PubMed Central

15 August 2017

L Cany

6

1 reference

Europe PubMed Central

15 August 2017

R Gaston

7

1 reference

Europe PubMed Central

15 August 2017

B N Bui

9

1 reference

Europe PubMed Central

15 August 2017

language of work or name

0 references

publication date

1 December 2003

1 reference

Europe PubMed Central

15 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

15 August 2017

89

1 reference

Europe PubMed Central

15 August 2017

12

1 reference

Europe PubMed Central

15 August 2017

2213-2218

1 reference

Europe PubMed Central

15 August 2017

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6601419

0 references

Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395282

30 September 2017

Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395282

30 September 2017

Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395282

30 September 2017

Biomodulation of 5-fluorouracil by interferon-alpha in human renal carcinoma cells: relationship to the expression of thymidine phosphorylase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395282

30 September 2017

An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395282

30 September 2017

Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395282

30 September 2017

A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395282

30 September 2017

Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395282

30 September 2017

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395282

30 September 2017

Chemotherapy for advanced renal-cell carcinoma: 1983-1993.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395282

30 September 2017

Reporting results of cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395282

30 September 2017

Evaluation of survival data and two new rank order statistics arising in its consideration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395282

30 September 2017

Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395282

28 June 2018

Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administrat

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395282

28 June 2018

Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395282

28 June 2018

Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395282

28 June 2018

Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395282

28 June 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6601419

21 January 2018

European studies of interleukin-2 in metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395282

20 October 2018

The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

1 reference

https://pubmed.ncbi.nlm.nih.gov/14676797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon inhibition of thymidine incorporation into DNA through effects on thymidine transport and uptake

1 reference

https://pubmed.ncbi.nlm.nih.gov/14676797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon effects upon fluorouracil metabolism by HL-60 cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/14676797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/14676797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/14676797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A progress report on the outpatient treatment of patients with advanced renal cell carcinoma using subcutaneous recombinant interleukin-2

1 reference

https://pubmed.ncbi.nlm.nih.gov/14676797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-2 in neoadjuvant therapy potentiates inhibitory activity of 5-fluorouracil and interferon in experimental liver metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/14676797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape

1 reference

https://pubmed.ncbi.nlm.nih.gov/14676797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-alpha for the treatment of patients with advanced renal cell carcinoma: a southwest oncology group Phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/14676797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/14676797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie

1 reference

https://pubmed.ncbi.nlm.nih.gov/14676797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second-line therapy with interferon-alpha plus vinblastine in metastatic renal cell cancer patients progressed under interleukin-2 subcutaneous immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/14676797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil

1 reference

https://pubmed.ncbi.nlm.nih.gov/14676797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/14676797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://pubmed.ncbi.nlm.nih.gov/14676797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators

1 reference

https://pubmed.ncbi.nlm.nih.gov/14676797

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6601419

1 reference

Europe PubMed Central

15 August 2017

Dimensions Publication ID

0 references

release_p2hxwdoparf3bhkd2zp34vt5yu

1 reference

https://api.fatcat.wiki/v0/release/p2hxwdoparf3bhkd2zp34vt5yu

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36673573&oldid=2050075002"